Cargando…

Monitoring Value of Serum HER2 as a Predictive Biomarker in Patients with Metastatic Breast Cancer

PURPOSE: The aim of this study was to investigate the monitoring value of serum HER2 in patients with metastatic breast cancer. PATIENTS AND METHODS: We firstly evaluated the association of serum HER2 levels with tissue HER2 expression and imaging results in 420 breast cancer patients admitted into...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Pengyu, Xiao, Jun, Ruan, Yingxin, Zhang, Zhenzhen, Zhang, Xuejun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308125/ https://www.ncbi.nlm.nih.gov/pubmed/32606958 http://dx.doi.org/10.2147/CMAR.S254897

Ejemplares similares

Association of serum follistatin levels with histological types and progression of tumor in human lung cancer
por: Zhang, Pengyu, et al.
Publicado: (2018)

Monitoring serum HER2 levels in breast cancer patients
por: Tchou, Julia, et al.
Publicado: (2015)

Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer
por: Shi, Hong-Zhi, et al.
Publicado: (2017)

Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer
por: Lam, Lian, et al.
Publicado: (2014)

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
por: Shao, Bin, et al.
Publicado: (2022)

Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker
por: Liu, Yi, et al.
Publicado: (2013)

Prognostic Value of HER2-Low Expression in Non-Metastatic Triple-Negative Breast Cancer and Correlation with Other Biomarkers
por: Jacot, William, et al.
Publicado: (2021)

Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies
por: Esteva, Francisco J, et al.
Publicado: (2005)

A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients
por: Li, Huiping, et al.
Publicado: (2018)

Association Between the HER2 Protein Expression Level and the Efficacy of Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
por: Yan, Hui, et al.
Publicado: (2020)

How to Manage and Monitor Cardiac Dysfunction in Patients With Metastatic HER2-Positive Breast Cancer
por: Dent, Susan F., et al.
Publicado: (2022)

Changes in Biomarker Status in Metastatic Breast Cancer and Their Prognostic Value
por: Woo, Ji Won, et al.
Publicado: (2019)

Prognostic Value of the Serum HER2 Extracellular Domain Level in Breast Cancer: A Systematic Review and Meta-Analysis
por: Wu, Yun, et al.
Publicado: (2022)

HER2-HER3 dimer quantification by FLIM-FRET predicts breast cancer metastatic relapse independently of HER2 IHC status
por: Weitsman, Gregory, et al.
Publicado: (2016)

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
por: Chiu, Joanne, et al.
Publicado: (2023)

The Value of Tucatinib in Metastatic HER2-Positive Breast Cancer Patients: An Italian Cost-Effectiveness Analysis
por: Antonazzo, Ippazio Cosimo, et al.
Publicado: (2023)

Expression and prognostic value of HER-2/neu in primary breast cancer with sentinel lymph node metastasis
por: Tong, Zhen-Jun, et al.
Publicado: (2017)

Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients
por: Asgeirsson, Kristjan S, et al.
Publicado: (2007)

Predictive value of angiogenesis-related gene profiling in patients with HER2-negative metastatic breast cancer treated with bevacizumab and weekly paclitaxel
por: Mendiola, Marta, et al.
Publicado: (2016)

Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
por: Ran, Ran, et al.
Publicado: (2020)

Predicting brain metastases of breast cancer based on serum S100B and serum HER2
por: BECHMANN, TROELS, et al.
Publicado: (2013)

Elevated serum HER‐2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression
por: Zheng, Hui, et al.
Publicado: (2019)

Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Sun, Ying, et al.
Publicado: (2021)

The role of irreversible pan-HER tyrosine kinase inhibitors in the treatment of HER2-Positive metastatic breast cancer
por: Wu, Zihong, et al.
Publicado: (2023)

An Update on the Prognostic and Predictive Serum Biomarkers in Metastatic Prostate Cancer
por: Saxby, Helen, et al.
Publicado: (2020)

HER3 and LINC00052 interplay promotes tumor growth in breast cancer
por: Salameh, Ahmad, et al.
Publicado: (2016)

Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations
por: Tian, Hao, et al.
Publicado: (2023)

Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia
por: Bai, Ju, et al.
Publicado: (2014)

Circulating metabolites serve as diagnostic biomarkers for HER2‐positive breast cancer and have predictive value for trastuzumab therapy outcomes
por: Mao, Changfei, et al.
Publicado: (2022)

Temporal Heterogeneity of HER2 Expression and Spatial Heterogeneity of (18)F-FDG Uptake Predicts Treatment Outcome of Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer
por: Gong, Chengcheng, et al.
Publicado: (2022)

Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients
por: Zhang, Shaohua, et al.
Publicado: (2016)

MAF1 is a predictive biomarker in HER2 positive breast cancer
por: Cabarcas-Petroski, Stephanie, et al.
Publicado: (2023)

Impact of residual disease biomarkers on the prognosis of HER2‐positive breast cancer following neoadjuvant therapy
por: Ma, Youzhao, et al.
Publicado: (2023)

The role of her2-targeted therapies in women with her2-overexpressing metastatic breast cancer
por: Dent, S., et al.
Publicado: (2009)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
por: Pizzuti, Laura, et al.
Publicado: (2021)

Serum HER2 Level Measured by Dot Blot: A Valid and Inexpensive Assay for Monitoring Breast Cancer Progression
por: Tan, Li-Duan, et al.
Publicado: (2011)

Correction to: Serum peptidome based biomarkers searching for monitoring minimal residual disease in adult acute lymphocytic leukemia
por: Bai, Ju, et al.
Publicado: (2020)

An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies
por: Perrier, Alexandre, et al.
Publicado: (2020)

Diagnostic value of serum HER2 levels in breast cancer: a systematic review and meta-analysis
por: Shamshirian, Amir, et al.
Publicado: (2020)

Targeted therapies for ER+/HER2- metastatic breast cancer
por: Yamamoto-Ibusuki, Mutsuko, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_p0d4rso2vip43obumqh6k1a6mp